Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Cash & Current Investments (2016 - 2025)

Nephros has reported Cash & Current Investments over the past 16 years, most recently at $5.4 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $5.4 million for Q4 2025, up 43.62% from a year ago — trailing twelve months through Dec 2025 was $5.4 million (up 43.62% YoY), and the annual figure for FY2025 was $5.4 million, up 43.62%.
  • Cash & Current Investments for Q4 2025 was $5.4 million at Nephros, up from $5.2 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for NEPH hit a ceiling of $8.3 million in Q2 2021 and a floor of $2.5 million in Q3 2024.
  • Median Cash & Current Investments over the past 5 years was $4.2 million (2022), compared with a mean of $4.9 million.
  • Biggest five-year swings in Cash & Current Investments: tumbled 49.52% in 2022 and later surged 110.46% in 2025.
  • Nephros' Cash & Current Investments stood at $7.0 million in 2021, then crashed by 47.88% to $3.6 million in 2022, then increased by 18.52% to $4.3 million in 2023, then decreased by 12.7% to $3.8 million in 2024, then skyrocketed by 43.62% to $5.4 million in 2025.
  • The last three reported values for Cash & Current Investments were $5.4 million (Q4 2025), $5.2 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.